政府工作报告连续三年点名“创新药”

Core Viewpoint - The article emphasizes the Chinese government's commitment to promoting the high-quality development of innovative drugs and medical devices, alongside the expansion of commercial health insurance, as part of its efforts to improve public health and meet diverse medical needs [3]. Group 1: Government Initiatives - The government work report for 2026 reiterates the focus on "innovative drugs" for the third consecutive year, highlighting the need for high-quality development in this sector [3]. - In 2025, China approved a record 76 innovative drugs for market entry, surpassing the 48 approved in 2024, indicating a significant increase in innovation [3]. - The total value of authorized transactions for innovative drugs exceeded $130 billion in 2025, with over 150 transactions, marking a historic high [3]. Group 2: Commercial Health Insurance Development - The average annual growth rate of commercial health insurance has exceeded 20% over the past decade, with over 11,000 medical insurance products currently available [4]. - In 2025, the premium for commercial health insurance reached 997.3 billion yuan, still falling short of the 1 trillion yuan milestone [4]. - The focus for 2026 will be on expanding the scale of commercial health insurance, particularly through the development of a multi-layered security mechanism [4]. Group 3: Key Focus Areas for 2026 - The potential for cross-departmental data sharing in medical expenses, health check-ups, and imaging tests is a key area of focus, contingent on the opening of medical insurance data [5]. - The effectiveness of the newly established commercial insurance catalog for innovative drugs in driving sales and facilitating one-stop settlement for hospital and insurance payments is under scrutiny [5]. - The impact of tax policies on corporate willingness to invest in employee benefits and the potential for local tax incentives to support the growth of commercial health insurance are critical considerations [5]. Group 4: Innovations in Insurance Products - Regions like Shanghai, Guangdong, and Beijing are encouraging innovation in group insurance products, with a focus on enhancing coverage for innovative drugs and medical devices [6]. - The introduction of long-term care insurance is gaining attention, with the government promoting a basic level of care that can be complemented by commercial long-term care insurance for diverse family needs [6].